Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer

NCT02599454 is registered in ClinicalTrials.gov with Megan Daly, MD as lead sponsor.

NCT NCT02599454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02599454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer
Lead sponsor
Megan Daly, MD
Phase
Phase 1
Overall status
Completed
Start date
April 26, 2018
Completion date
February 20, 2024
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage i non-small cell lung cancer